
As OTC drink-spiking detection products become more widely available, pharmacists can play a critical role in counseling patients on their benefits, limitations, and appropriate response to suspected drink tampering.

As OTC drink-spiking detection products become more widely available, pharmacists can play a critical role in counseling patients on their benefits, limitations, and appropriate response to suspected drink tampering.

The FDA clears roflumilast, a PDE4 inhibitor, for once-daily steroid-free plaque psoriasis care in kids ages 2+.

Findings from a multicenter cohort study suggest glucagon-like peptide-1 (GLP-1) receptor agonist therapy may be associated with an elevated risk of sensory disturbances.

The approval adds a 55-mg prefilled syringe for weight-based dosing and makes risankizumab the first IL-23 inhibitor cleared for pediatric patients weighing less than 40 kg.

AML and menin inhibitors transform acute myeloid leukemia treatment: FDA-approved choices, MEN1 protein target, and bedside toxicity monitoring.

PCOS becomes PMOS, spotlighting metabolic and endocrine risks.

Be confident that you have researched all avenues and feel secure in making your recommendations.

Veligrotug-vvze is the first FDA-approved thyroid eye disease treatment with data in both active and chronic disease.

A compliance expert outlines what's next for GLP-1 compounding oversight and how pharmacists can stay audit-ready.

Biosimilars are equally safe and cut costs. Pharmacists can ease patient fears at the counter.

Interim data, briefly held back from the CDC’s weekly report, show the reformulated shot added meaningful protection even among adults with substantial existing immunity.

Compared with placebo, adult patients with ADHD and comorbid anxiety had greater change from baseline in AISRS total score at week 8.

Timothy Clifford, PharmD, outlines how quality-of-life impact, comorbid conditions, and prior therapy failures guide biologic selection for CRSwNP.

Aderonke Adeboye, PharmD, discusses the clinical red flags that signal a patient with CSU needs advanced therapy and how specialty pharmacists guide treatment selection and support long-term adherence for biologics and emerging oral agents.

Oral semaglutide delivers significant weight loss in OASIS trials, offering needle-free obesity therapy.

GoodRx's David Graziano breaks down how fluctuating acquisition costs, narrow formularies, and retrospective reimbursement adjustments are squeezing independent pharmacies—and what solutions exist to help them remain competitive.

Monica Dougherty, PharmD, BCACP, explains how the 2026 GOLD guideline updates use blood eosinophil counts to guide biologic therapy decisions for patients with COPD.

This FAQ outlines current measles cases, key drivers of increasing cases, and the essential role pharmacists play in vaccination, patient counseling, case recognition, and combating vaccine misinformation.

Pharmacists who understand the workflow before July 1 will be the ones patients and prescribers depend on when the program launches.

Suzanne Feeney, PharmD, explains why expanding clinical services—from immunizations to chronic disease management—is a critical growth strategy for independent pharmacies navigating reimbursement pressures and shifting legislation.

The agent is to be used alongside diet adjustments in adult patients.

As these tools continue to move into mainstream diabetes management, it is increasingly important that pharmacists have proficiency.

A compliance expert breaks down the FDA's move to exclude glucagon-like peptide-1 (GLP-1) drugs from the 503B bulk's list and what it means for pharmacists and patients.

Shahida Choudhry, PharmD, discusses earning McKesson ideaShare's inaugural Trailblazer Award, building an integrated primary care and pharmacy model, and using advocacy and social media to elevate independent pharmacy.

Marijuana’s move to Schedule III has reignited a long-standing contradiction.

Chiadi Ndumele, MD, breaks down the cardiovascular-kidney-metabolic syndrome (CKM) guideline's glucagon-like peptide-1 (GLP-1) and kidney-protective therapy guidance—and the pharmacist's role in coordinated care.

On GLP-1s like semaglutide or tirzepatide, weight loss can mean muscle loss; encourage patients to use protein and resistance training to stay strong.

Incorporate important health screenings and lifestyle prevention tips in MTM consults.

From AI-driven dispensing to grassroots advocacy wins, here are the key insights Pharmacy Times gathered at McKesson ideaShare 2026 in Denver.

Specialty dispensing and infusion services offer real opportunity—but the path requires careful planning, sequencing, and the right resources.